{"id":54571,"date":"2021-11-18T04:35:28","date_gmt":"2021-11-17T23:05:28","guid":{"rendered":"https:\/\/centralrecorder.com\/1st-human-trial-of-alzheimers-disease-nasal-vaccine-after-20-years-of-research-will-begin-at-boston-hospital\/"},"modified":"2021-11-18T04:36:26","modified_gmt":"2021-11-17T23:06:26","slug":"boston-hospital-will-host-the-first-human-trial-of-alzheimers-disease-nasal-vaccine-after-20-years-of-research","status":"publish","type":"post","link":"https:\/\/centralrecorder.com\/boston-hospital-will-host-the-first-human-trial-of-alzheimers-disease-nasal-vaccine-after-20-years-of-research\/","title":{"rendered":"Boston Hospital will host the first human trial of Alzheimer’s Disease Nasal Vaccine after 20 years of research"},"content":{"rendered":"\n
A groundbreaking clinical trial of a nasal vaccine for Alzheimer’s disease that has been decades in the making is set to begin at Brigham and Women\u2019s Hospital in Boston, according to hospital officials.\u00a0<\/p>\n
The goal of the trial is to test the safety and efficacy of the vaccine that is delivered nasally and intended to prevent and slow the progression of Alzheimer\u2019s disease (AD).\u00a0<\/p>\n
Dr. Howard L. Weiner, co-director of the Ann Romney Center for Neurological Diseases at Brigham described the launch of the first human trial of a nasal vaccine for Alzheimer\u2019s disease, \u201ca remarkable milestone.\u201d<\/p>\n
The clinical\u00a0trial will include 16 participants between the ages of 60 and 85, who all show early symptomatic Alzheimer\u2019s, but are otherwise generally healthy, the hospital said in aPress release<\/a><\/p>\n Each person will be given two doses of vaccine, one each week. According to the release, participants will register at the Ann Romney Center.<\/p>\n Researchers believe the vaccine contains Protollin, a substance that stimulates the immune system. It has also been shown to be safe in other vaccines.<\/p>\n “Protollin is designed to activate white blood cells found in the lymph nodes on the sides and back of the neck to migrate to the brain and trigger clearance of beta-amyloid plaques \u2014 one of the hallmarks of Alzheimer\u2019s disease,\u201d according to the release.\u00a0<\/p>\n Researchers said phase I trial’s primary objective will be to “To determine safety and tolerability,” and observe how Protollin affects participants’ immune response, including how it affects their white blood cells.<\/p>\n